Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
inflammation
Biotech
Tiziana to spin out IL-6 drug, cites pharma interest in modality
Tiziana has pointed to increased Big Pharma interest in the IL-6 pathway as justification for spinning out its own candidate into a separate company.
James Waldron
Dec 2, 2025 8:45am
Inflammation biotech Evommune heads to NYSE with $150M IPO
Nov 6, 2025 7:00am
Neurocrine pens $880M pact with TransThera for immunology target
Nov 3, 2025 5:42am
Biogen pens $1B deal for Vanqua's preclinical C5aR1 antagonist
Oct 24, 2025 9:15am
HCW Biologics clings on with $5M lifeline to fund alopecia trial
May 16, 2025 7:00am
Gilead roars into JPM25 with $250M upfront deal for Leo
Jan 11, 2025 5:30pm
